SCHEMBL6412445

SCHEMBL6412445

CN(Cc1cccc(F)c1)C(=O)C=C(O)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.56
KMT2A Q03164 5/20 0.56
RIPK1 Q13546 1/20 0.54
SCD5 Q86SK9 1/20 0.49
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
LIPE Q05469 1/20 0.45
FOLH1 Q04609 1/20 0.44
CLK1 P49759 1/20 0.44
CLK2 P49760 1/20 0.44
DYRK1A Q13627 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44
DYRK1B Q9Y463 1/20 0.44
HCAR2 Q8TDS4 2/20 0.44
HSD17B1 P14061 1/20 0.43
HSD17B2 P37059 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SLC6A2 P23975 1/20 0.42
SLC6A3 Q01959 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6412442 1.00 MEN1 (0.56) MEN1KMT2ARIPK1SCD5ALDH1A1
SCHEMBL6418747 0.87 MEN1 (0.52) MEN1KMT2ARIPK1SCD5ALDH1A1
SCHEMBL6418741 0.87 MEN1 (0.52) MEN1KMT2ARIPK1SCD5ALDH1A1
SCHEMBL6421148 0.86 KMT2A (0.43) MEN1KMT2ARIPK1SCD5ALDH1A1
SCHEMBL6421144 0.86 KMT2A (0.43) MEN1KMT2ARIPK1SCD5ALDH1A1
SCHEMBL6417796 0.86 AOC3 (0.51) HSD17B1HSD17B2
SCHEMBL6417801 0.86 AOC3 (0.51) HSD17B1HSD17B2
SCHEMBL17266198 0.84 MEN1 (0.67) MEN1KMT2ARIPK1SCD5ALDH1A1
SCHEMBL6412481 0.84 NPC1 (0.56) MEN1KMT2ARIPK1ALDH1A1HPGD
SCHEMBL6412477 0.84 NPC1 (0.56) MEN1KMT2ARIPK1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043370-A1 HIV integrase inhibitors WALKER MICHAEL A (US) 2005-02-24 US disclosed
US-6803378-B2 FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC BRISTOL-MYERS SQUIBB COMPANY 2004-10-12 US disclosed
US-20030181490-A1 HIV integrase inhibitors WALKER MICHAEL A (US) 2003-09-25 US disclosed
EP-1322599-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-02 EP disclosed
US-20030027847-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2003-02-06 US disclosed
WO-2001096283-A9 HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2002-10-17 WO disclosed
WO-2001096283-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043370-A1 HIV integrase inhibitors AKR1C3, CBR3, CBR1 MEN1 4741/4885KMT2A 1208/4885RIPK1 3528/4885
US-20030181490-A1 HIV integrase inhibitors CBR1, CCR5, CCR1 MEN1 4837/4885KMT2A 1330/4885RIPK1 3530/4885
US-20030027847-A1 HIV integrase inhibitors CBR1, CCR5, CCR1 MEN1 4837/4885KMT2A 1330/4885RIPK1 3530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.